Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
STGW$8.62-0.36(-4.01%)Stagwell (STGW) Acquires Freestar, Leading Publisher Advertising Services Company[11:30:00 AM ET]PGNY$28.52-0.45(-1.55%)New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model[11:25:22 AM ET]PII$55.23+0.41(+0.75%)POLARIS SIGNS OFF-ROAD CHAMPION KYLE CHANEY TO MULTI-YEAR RACING AGREEMENT WITH RZR FACTORY RACING[11:22:00 AM ET]LLY$1,275.02+1.56(+0.12%)Lilly declares fourth-quarter 2026 dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2026 of $1.73 per share on outstanding...[11:19:00 AM ET]NWBO$0.15+0.00(+0.20%)Northwest Biotherapeutics Announces Expansion of Its Technical Team Northwest Biotherapeutics (OTCQB: NWBO) NWBio a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...[11:16:00 AM ET]SFD$18.33-0.31(-1.64%)Smithfield Foods Establishes $250,000 Future Leaders Scholarship Program at Christopher Newport University[11:00:00 AM ET]HAMRF$0.04-0.00(-5.58%)Silver Hammer Provides Exploration and Corporate Update[11:00:00 AM ET]FRHC$173.70+2.48(+1.45%)Freedom Holding Corp. Advances AI Infrastructure Development in Kazakhstan Freedom Holding Corp. (Nasdaq: FRHC) is advancing its AI infrastructure plans in Kazakhstan, including a $2 billion Sovereign AI Hub and the launch...[11:00:00 AM ET]EPOW$4.26+0.71(+20.20%)E-Power’s Guizhou Joint Venture Receives RMB 110 Million of RMB 200 Million Capital Increase at RMB 2.0 Billion Post-Money Valuation[11:00:00 AM ET]MTB$223.06+1.40(+0.63%)M&T Bank and Wilmington Trust Name Brian Green New Chief Investment Officer M&T Bank Corp. (NYSE: MTB) announced that Brian Green has been named Chief Investment Officer for M&T Bank and Wilmington Trust effective today. In...[11:00:00 AM ET]BBTT$0.02-0.01(-29.19%)Btab Launches AI-Powered Btab.app to Connect Manufacturers and Entrepreneurs Through Its Global Commerce Ecosystem[10:55:00 AM ET]

BMRN · NASDAQ

BioMarin Pharmaceutical Inc.

$55.64 -0.31 (-0.55%)

Company overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$10.8B
Employees
3,040
Headquarters
San Rafael, CA
Website
biomarin.com
CEO
Alexander Hardy
Listed
July 26, 1999
P/E
39.67
Dividend yield
0.00%

Company financials

Revenue
$3.2B
Gross profit
$2.5B
Operating income
$439M
EBITDA
$482M
Net income
$269M
EPS
$1.40
Total assets
$8.6B
Total debt
$1.4B
Gross margin
75.93%
Net margin
8.29%
Earnings yield
2.52%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No annual geographic segmentation.

Showing FY 2025

Price chart

48.3954.2560.1265.9871.85
BMRN 1D NASDAQ O56.68H56.81L55.24C55.95-0.68 (-1.20%)Vol1.68M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Type
Ticker Type Headline Source Published
BMRNBioMarin Pharmaceutical Inc. Press release BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET PRNewsWire
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? Zacks Investment Research
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers Position Defense World
BMRNBioMarin Pharmaceutical Inc. Stock news Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock Zacks Investment Research
BMRNBioMarin Pharmaceutical Inc. Stock news Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN) Defense World
BMRNBioMarin Pharmaceutical Inc. Press release BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting BioMarin Pharmaceutical Inc. PR Newswire
BMRNBioMarin Pharmaceutical Inc. Press release BioMarin Appoints Cara Bauer as Chief People Officer PRNewsWire
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin reports five-year Pompe disease data showing durable motor function CNBC
BMRNBioMarin Pharmaceutical Inc. Press release BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress PR Newswire
BMRNBioMarin Pharmaceutical Inc. Press release Profluent Partners With BioMarin to Design Novel Medicines Using AI Business Wire
BMRNBioMarin Pharmaceutical Inc. Stock news Reviewing Metagenomi (NASDAQ:MGX) and BioMarin Pharmaceutical (NASDAQ:BMRN) Defense World
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin: Why I See Significant Upside Into 2027 Seeking Alpha
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone MarketBeat
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin Stops Voxzogo Development for Noonan Syndrome Zacks Investment Research
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
BMRNBioMarin Pharmaceutical Inc. Press release BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors PR Newswire
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Seeking Alpha
BMRNBioMarin Pharmaceutical Inc. Stock news BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Seeking Alpha
BMRNBioMarin Pharmaceutical Inc. Press release BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence PR Newswire
See more
FAQ

Questions about BioMarin Pharmaceutical Inc.

What does BioMarin Pharmaceutical Inc. do?
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
What is BMRN's market cap?
BioMarin Pharmaceutical Inc. (BMRN) is a listed stock with a live quote. The latest market cap on this page is $10.8B.
Where is BioMarin Pharmaceutical Inc. headquartered?
BioMarin Pharmaceutical Inc. is headquartered in San Rafael, CA.
How do I get BMRN news from the API?
Call GET /v1/news?tickers=BMRN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does BMRN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for BMRN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the BMRN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs